An amendment numbered 5 printed in House Report 116-61 to Commission a study by the National Academy of Medicine into the amount of federal funding and research used in the development of drugs by pharmaceutical companies, and to put measures in place to curb excessive drug costs.

passedUnited States· United States Congress· EN

Introduced

—

Last action

—

Status

On agreeing to the DeSaulnier amendment (A005) Agreed to by voice vote.

Records

Official amendment HAMDT 224 (116th) from United States at United States Congress. Status: On agreeing to the DeSaulnier amendment (A005) Agreed to by voice vote..

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Vertaal naar

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Related records

amends → Strengthening Health Care and Lowering Prescription Drug Costs Act

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/amendment/116th-congress/hamdt-224
Open data entity: https://api.congress.gov/v3/amendment/116/hamdt/224
us · 116-hamdt-224 · source updated 9 February 2022